

Customer Number: 20462
Attorney Docket No.: PB60196
Confirmation Number: 8326

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Aston, N.
Serial No.: 10/551,501 Group Art Unit: 1621
Filed: 25 May 2006 Examiner: S. Kumar
For: BIPHENYLCARBOXYLIC AMIDE DERIVATIVES AS P38
KINASE INHIBITORS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

TERMINAL DISCLAIMER UNDER 37 CFR §1.321

Sir:

SmithKline Beecham Corporation, of One Franklin Plaza, Philadelphia, Pennsylvania 19103, represents that it is the assignee of all title and interest as recorded on 25 May 2006, at Reel 017680, and Frame 0834. The present application is the §371 national stage entry of PCT/EP2004/003773. Assignee represents that it is the assignee of record in US application Serial Number 10/492,698, filed 8 August 2004, by virtue of an assignment recorded on Reel 015071, Frame 0911.

Assignee hereby disclaims, except as provided below, the terminal part of the statutory term of any patent granted on the present application which would extend beyond the expiration date of the earlier of the full statutory term defined in 35 USC §154 and §156 of any patent granted on US application Serial Number 10/492,698, and, if a patent is granted on US application Serial Number 10/492,698 hereby agrees that any patent so granted on the present application shall be enforceable only for and during such period that the legal title to said patent shall be the same as the legal title to any patent granted on US application Serial Number 10/492,698. This agreement is to run with any

patent granted on the present application and to be binding upon the grantee, its successors or assigns.


In making the above disclaimer, Assignee does not disclaim any terminal part of any patent granted on the present application prior to the expiration date of the earlier of the full statutory term defined in 35 USC §154 of any patent granted on US application Serial Number 10/492,698 in the event that said patent granted on US application Serial Number 10/492,698, is abandoned, expires for failure to pay a maintenance fee, is held unenforceable or is found invalid by a court of competent jurisdiction, is statutorily disclaimed in whole or terminally disclaimed under 37 CFR 1.321(a), has all claims cancelled by a reexamination certificate, or is otherwise not deemed to provide the rights conveyed by 35 USC §154 prior to the expiration of its full statutory term as presently shortened by any terminal disclaimer, except for the separation of legal title stated above. This disclaimer shall not be effective against any patent term extensions obtained under 35 USC §156 for any patent granted on the present application.

Please charge the \$110.00 fee required by this Terminal Disclaimer under 37 CFR 1.20(d) to Deposit Account Number 19-2570.

Also should the Commissioner determine that said fee is not sufficient to have this paper entered, the Commissioner is hereby authorized to charge any such fee that may be required by this petition or to credit any over payment to said deposit account.

Dated: 26 January 2007

Respectfully submitted,



Dara L. Dinner
Attorney for Applicants
Registration No. 33,680

GLAXOSMITHKLINE
Corporate Intellectual Property - UW2220
P.O. Box 1539
King of Prussia, PA 19406-0939
Phone (610) 270-5017
Facsimile (610) 270-5090